Shares of Lupin will remain in focus after the company said it has received final approval from the US health regulator to sell generic diabetes management drug Pioglitazone Tablets in the US market. The announcement was made during the market’s closing hours on Wednesday. Lupin has said its subsidiary will shortly commence marketing the product, which has annual sales of $236 million in the US. The stock saw FII holding dip to 31.86 per cent (March end) from 31.92 per cent (December end).
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.